194 related articles for article (PubMed ID: 24876881)
1. In Silico Investigation of Potential PARP-1 Inhibitors from Traditional Chinese Medicine.
Chen KC; Sun MF; Chen CY
Evid Based Complement Alternat Med; 2014; 2014():917605. PubMed ID: 24876881
[TBL] [Abstract][Full Text] [Related]
2. In silico investigation of potential mTOR inhibitors from traditional Chinese medicine for treatment of Leigh syndrome.
Chen KC; Lee WY; Chen HY; Chen CY
Biomed Res Int; 2014; 2014():139492. PubMed ID: 25045657
[TBL] [Abstract][Full Text] [Related]
3. Poly(ADP-ribose) polymerase-1 activation during DNA damage and repair.
Dantzer F; Amé JC; Schreiber V; Nakamura J; Ménissier-de Murcia J; de Murcia G
Methods Enzymol; 2006; 409():493-510. PubMed ID: 16793420
[TBL] [Abstract][Full Text] [Related]
4. Natural inhibitors of poly(ADP-ribose) polymerase-1.
Banasik M; Stedeford T; Strosznajder RP
Mol Neurobiol; 2012 Aug; 46(1):55-63. PubMed ID: 22476980
[TBL] [Abstract][Full Text] [Related]
5. Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy.
Cepeda V; Fuertes MA; Castilla J; Alonso C; Quevedo C; Soto M; Pérez JM
Recent Pat Anticancer Drug Discov; 2006 Jan; 1(1):39-53. PubMed ID: 18221025
[TBL] [Abstract][Full Text] [Related]
6. PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling.
van Beek L; McClay É; Patel S; Schimpl M; Spagnolo L; Maia de Oliveira T
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34066057
[TBL] [Abstract][Full Text] [Related]
7. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.
Peralta-Leal A; Rodríguez-Vargas JM; Aguilar-Quesada R; Rodríguez MI; Linares JL; de Almodóvar MR; Oliver FJ
Free Radic Biol Med; 2009 Jul; 47(1):13-26. PubMed ID: 19362586
[TBL] [Abstract][Full Text] [Related]
8. In silico investigation of potential SRC kinase ligands from traditional Chinese medicine.
Tou WI; Chen CY
PLoS One; 2012; 7(3):e33728. PubMed ID: 22470466
[TBL] [Abstract][Full Text] [Related]
9. Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP) - Function in Genome Maintenance and Relevance of Inhibitors for Anti-cancer Therapy.
Harrision D; Gravells P; Thompson R; Bryant HE
Front Mol Biosci; 2020; 7():191. PubMed ID: 33005627
[TBL] [Abstract][Full Text] [Related]
10. The
Taipakova S; Kuanbay A; Saint-Pierre C; Gasparutto D; Baiken Y; Groisman R; Ishchenko AA; Saparbaev M; Bissenbaev AK
Front Cell Dev Biol; 2020; 8():606596. PubMed ID: 33324653
[TBL] [Abstract][Full Text] [Related]
11. Effect of simulated microgravity conditions on poly(ADP-ribose) polymerase activity in primary cultures of adult rat hepatocytes.
Cesarone CF; Pippia P; Demori I; Scarabelli L; Fugassa E
J Gravit Physiol; 2001 Jul; 8(1):P127-8. PubMed ID: 12650200
[TBL] [Abstract][Full Text] [Related]
12. New perspectives on the plant PARP family: Arabidopsis PARP3 is inactive, and PARP1 exhibits predominant poly (ADP-ribose) polymerase activity in response to DNA damage.
Gu Z; Pan W; Chen W; Lian Q; Wu Q; Lv Z; Cheng X; Ge X
BMC Plant Biol; 2019 Aug; 19(1):364. PubMed ID: 31426748
[TBL] [Abstract][Full Text] [Related]
13. A Review on DNA Repair Inhibition by PARP Inhibitors in Cancer Therapy.
Shah AP; Patel CN; Sureja DK; Sanghavi KP
Folia Med (Plovdiv); 2018 Mar; 60(1):39-47. PubMed ID: 29668451
[TBL] [Abstract][Full Text] [Related]
14. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors.
Virág L; Szabó C
Pharmacol Rev; 2002 Sep; 54(3):375-429. PubMed ID: 12223530
[TBL] [Abstract][Full Text] [Related]
15. Poly(ADP-ribose) polymerase-1 protects excessive DNA strand breaks from deterioration during repair in human cell extracts.
Parsons JL; Dianova II; Allinson SL; Dianov GL
FEBS J; 2005 Apr; 272(8):2012-21. PubMed ID: 15819892
[TBL] [Abstract][Full Text] [Related]
16. PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis.
Langelier MF; Pascal JM
Curr Opin Struct Biol; 2013 Feb; 23(1):134-43. PubMed ID: 23333033
[TBL] [Abstract][Full Text] [Related]
17. Poly (adp-ribose) polymerase inhibitors as potential therapeutic agents in stroke and neurotrauma.
Komjáti K; Besson VC; Szabó C
Curr Drug Targets CNS Neurol Disord; 2005 Apr; 4(2):179-94. PubMed ID: 15857303
[TBL] [Abstract][Full Text] [Related]
18. Quantitative site-specific ADP-ribosylation profiling of DNA-dependent PARPs.
Gagné JP; Ethier C; Defoy D; Bourassa S; Langelier MF; Riccio AA; Pascal JM; Moon KM; Foster LJ; Ning Z; Figeys D; Droit A; Poirier GG
DNA Repair (Amst); 2015 Jun; 30():68-79. PubMed ID: 25800440
[TBL] [Abstract][Full Text] [Related]
19. A quantitative assay reveals ligand specificity of the DNA scaffold repair protein XRCC1 and efficient disassembly of complexes of XRCC1 and the poly(ADP-ribose) polymerase 1 by poly(ADP-ribose) glycohydrolase.
Kim IK; Stegeman RA; Brosey CA; Ellenberger T
J Biol Chem; 2015 Feb; 290(6):3775-83. PubMed ID: 25477519
[TBL] [Abstract][Full Text] [Related]
20. Computational investigation of FDA approved drugs as selective PARP-1 inhibitors by targeting BRCT domain for cancer therapy.
Kumar C; Lakshmi PTV; Arunachalam A
J Mol Graph Model; 2021 Nov; 108():107919. PubMed ID: 34304979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
